GU Cancers 2020 | STRONG: durvalumab for UC

Name: STRONG: durvalumab for UC
Uploaded: 2020-02-15T18:31:02Z
Description: Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the STRONG study (NCT03084471), an open-label, multi-centre, study to assess the safety of fixed-dose durvalumab in urothelial carcinoma (UC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Guru Sonpavde • 15 Feb 2020

GU Cancers 2020

Bladder Cancer Genitourinary Cancer Antibodies Durvalumab

STRONG

Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the STRONG study (NCT03084471), an open-label, multi-centre, study to assess the safety of fixed-dose durvalumab in urothelial carcinoma (UC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.